.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,872,133

« Back to Dashboard

Details for Patent: 5,872,133

Title: Method of regulating the immune response
Abstract:Methods for upregulating abnormal responses of the mammalian immune system are provided. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed is a method for administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals).
Inventor(s): Cincotta; Anthony H. (Andover, MA), Meier; Albert H. (Andover, MA)
Assignee: The Board of Supervisors of Louisiana University and Agricultural and Mechanical College (Baton Rouge, LA) N/A (Boston, MA) The General Hospital Corporation (N/A)
Filing Date:Jun 02, 1995
Application Number:08/458,960
Claims:1. A method for upregulating immune responses in a mammal in need of such treatment, which comprises:

delivering to said mammal a therapeutically effective amount of a prolactin enhancer in a dosage regimen under which the delivering of said prolactin enhancer is confined to the time interval when prolactin levels are high in young, healthy mammals of the same species.

2. A method for upregulating immune responses in a mammal in need of such treatment, which comprises:

delivering to said mammal a therapeutically effective amount of a prolactin enhancer in a dosage regimen under which the delivery of said prolactin enhancer is confined to the time period between 0 and 3 hours prior to the time interval when prolactin levels are high in a young, healthy mammal of the same species.

3. The method of claim 1 in which the mammal being treated is a human and the delivery of said prolactin enhancer is confined to the period from between 2200 and 0100 h.

4. The method of claim 1 wherein said prolactin enhancer is delivered to said human at night, within about one hour before said human's bedtime.

5. The method of claim 2 wherein said prolactin enhancer is delivered to said human at night, within about one hour before said human's bedtime.

6. In a method for upregulating immune responses in a mammal in need of such treatment by administration of therapeutically effective amount of a prolactin enhancer, the improvement which comprises:

confining delivery of said prolactin enhancer to the time interval when prolactin levels are high in young, healthy mammals of the same species.

7. In a method for upregulating immune responses in a mammal in need of such treatment by administration of therapeutically effective amount of a prolactin enhancer, the improvement which comprises:

confining delivery of said prolactin enhancer to the time period between 0 and 3 hours prior to the time interval when prolactin levels are high in a young, healthy mammal of the same species.

8. An improvement according to claim 6 in which the mammal being treated is a human.

9. An improvement according to claim 7 in which the mammal being treated is a human.

10. An improvement according to claim 8 in which said delivery of said prolactin enhancer is confined to the period about one hour before said human's bedtime.

11. An improvement according to claim 9 in which said delivery of said prolactin enhancer is confined to the period about one hour before said human's bedtime.

12. The method of claim 1 wherein said prolactin enhancer is selected from the group consisting of prolactin, metoclopramide, haloperidol, pimozide, phenothiazine, domperidone, sulpiride, chlorpromazine serotonin agonists that are MAO inhibitors, pargyline, methadone, estrogens, tryptophan, 5-hydroxytryptophan, fluoxitane, dexfenfluramine, and non-toxic salts thereof.

13. The method of claim 2 wherein said prolactin enhancer is selected from the group consisting of prolactin, metoclopramide, haloperidol, pimozide, phenothiazine, domperidone, sulpiride, chlorpromazine serotonin agonists that are MAO inhibitors, pargyline, methadone, estrogens, tryptophan, 5-hydroxytryptophan, fluoxitane, dexfenfluramine, and non-toxic salts thereof.

14. The method of claim 6 wherein said prolactin enhancer is selected from the group consisting of prolactin, metoclopramide, haloperidol, pimozide, phenothiazine, domperidone, sulpiride, chlorpromazine serotonin agonists that are MAO inhibitors, pargyline, methadone, estrogens, tryptophan, 5-hydroxytryptophan, fluoxitane, dexfenfluramine, and non-toxic salts thereof.

15. The method of claim 7 wherein said prolactin enhancer is selected from the group consisting of prolactin, metoclopramide, haloperidol, pimozide, phenothiazine, domperidone, sulpiride, chlorpromazine serotonin agonists that are MAO inhibitors, pargyline, methadone, estrogens, tryptophan, 5-hydroxytryptophan, fluoxitane, dexfenfluramine, and non-toxic salts thereof.

16. A method for upregulating immune response in a human in need of such treatment, which comprises:

delivering to said human a therapeutically effective amount of a prolactin enhancer in a dosage regimen under which the delivering of said prolactin enhancer is confined to the period from between 19:00 h and 07:00 h.

17. A method of claim 16, wherein said prolactin enhancer is delivered to said human at between 22:00 h and 01:00 h.

18. In a method for upregulating immune response in a human in need of such treatment by delivering to said human a therapeutically effective amount of a prolactin enhancer, the improvement which comprises:

confining delivery of said prolactin enhancer to the period from between 19:00 h and 07:00 h.

19. An improvement according to claim 18, wherein said prolactin enhancer is delivered to said human at between 22:00 h and 01:00 h.

20. An improvement according to claim 6 in which the mammal being treated is a human and the delivery of said prolactin enhancer is confined to the period from between 22:00 h and 01:00 h.

21. An improvement according to claim 7 in which the mammal being treated is a human and the delivery of said prolactin enhancer is confined to the period from between 22:00 h and 01:00 h.

22. The method of claim 16 wherein said prolactin enhancer is selected from the group consisting of prolactin, metoclopramide, haloperidol, pimozide, phenothiazine, domperidone, sulpiride, chlorpromazine serotonin agonists that are MAO inhibitors, pargyline, methadone, estrogens, tryptophan, 5-hydroxytryptophan,fluoxitane, dexfenfluramine, and non-toxic salts thereof.

23. The method of claim 18 wherein said prolactin enhancer is selected from the group consisting of prolactin, metoclopramide, haloperidol, pimozide, phenothiazine, domperidone, sulpiride, chlorpromazine serotonin agonists that are MAO inhibitors, pargyline, methadone, estrogens, tryptophan, 5-hydroxytryptophan,fluoxitane, dexfenfluramine, and non-toxic salts thereof.

24. The method of claim 1 wherein said prolactin enhancer is melatonin or a non-toxic salt thereof.

25. The method of claim 2 wherein said prolactin enhancer is melatonin or a non-toxic salt thereof.

26. The method of claim 6 wherein said prolactin enhancer is melatonin or a non-toxic salt thereof.

27. The method of claim 7 wherein said prolactin enhancer is melatonin or a non-toxic salt thereof.

28. The method of claim 16 wherein said prolactin enhancer is melatonin or a non-toxic salt thereof.

29. The method of claim 17 wherein said prolactin enhancer is melatonin or a non-toxic salt thereof.

30. The method of claim 18 wherein said prolactin enhancer is melatonin or a non-toxic salt thereof.

31. The method of claim 19 wherein said prolactin enhancer is melatonin or a non-toxic salt thereof.

32. The method of claim 17 wherein said prolactin enhancer is selected from the group consisting of prolactin, metoclopramide, haloperidol, pimozide, phenothiazine, domperidone, sulpiride, chlorpromazine serotonin agonists that are MAO inhibitors, pargyline, methadone, estrogens, tryptophan, 5-hydroxytryptophan,fluoxitane, dexfenfluramine, and non-toxic salts thereof.

33. The method of claim 19 wherein said prolactin enhancer is selected from the group consisting of prolactin, metoclopramide, haloperidol, pimozide, phenothiazine, domperidone, sulpiride, chlorpromazine serotonin agonists that are MAO inhibitors, pargyline, methadone, estrogens, tryptophan, 5-hydroxytryptophan,fluoxitane, dexfenfluramine, and non-toxic salts thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc